IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Orexigen Therapeutics Inc

CUSIP: 686164952 | 4 institutional holders

Quarters

Q2 2018Q1 2018Q4 2017Q3 2017Q2 2017
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile